Corium to Report Fourth Quarter and Year-end Fiscal Year 2016 Financial Results on Monday, November 21, 2016
November 15 2016 - 8:00AM
Corium International, Inc. (NASDAQ:CORI) today announced that it
will report financial results for the fourth quarter and fiscal
year (FY) ended September 30, 2016 on Monday, November 21,
2016 after the close of the U.S. financial markets. Corium
will host a conference call and live audio webcast at 5:00 p.m.
Eastern time, 2:00 p.m. Pacific time to discuss its
financial results and report on recent progress.
Conference Call and Webcast Details
Investors and analysts can access the call toll-free by dialing
(844) 831-3024 (United States) or +1 (315) 625-6887
(international). The conference ID# is 17537774. The
conference call also will be available via a live audio webcast
which may be accessed here, or by visiting “Events &
Presentations” in the Investors section of the Company’s website at
www.coriumgroup.com. The webcast will be archived on the
Corium website for two weeks following the presentation.
About Corium
Corium International, Inc. is a commercial-stage
biopharmaceutical company focused on the development, manufacture
and commercialization of specialty pharmaceutical products that
leverage the company's broad experience with advanced transdermal
and transmucosal delivery systems. Corium has multiple
proprietary programs in preclinical and clinical development,
focusing primarily on the treatment of neurological disorders, with
lead programs in Alzheimer's disease. Corium has developed
and is the sole commercial manufacturer of seven prescription drug
and consumer products with partners Mayne Pharma, Endo
Pharmaceuticals and Procter & Gamble. The company has two
proprietary transdermal platforms: Corplex™ for small molecules and
MicroCor®, a biodegradable microstructure technology for small
molecules and biologics, including vaccines, peptides and
proteins. The company's late-stage pipeline includes a
contraceptive patch co-developed with Agile Therapeutics that has
recently completed Phase 3 trials, and additional transdermal
products that are being developed with other partners. For
further information, please visit www.coriumgroup.com.
Corplex™ and MicroCor® are registered trademarks of Corium
International, Inc.
Investor and Media Contact:
SMP Communications
Susan Pietropaolo
spietropaolo@bccpartners.com
(201) 923-2049
CORIUM INTERNATIONAL, INC. (NASDAQ:CORI)
Historical Stock Chart
From Aug 2024 to Sep 2024
CORIUM INTERNATIONAL, INC. (NASDAQ:CORI)
Historical Stock Chart
From Sep 2023 to Sep 2024